Showing results (401-410 of 412) with videos related to

Sort By:
Pageof 42
Blood|March 22, 2003
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromesFrancis J Giles, Alison T Stopeck, Lewis R Silverman, et al.
Haematologica|December 1, 2020
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndromeAlana Vicente, Bhavisha A Patel, Fernanda Gutierrez-Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignanciesKaren W L Yee, Anne Hagey, Srdan Verstovsek, et al.
Journal of Clinical Microbiology|September 7, 2022
Effective Rapid Diagnosis of Bacterial and Fungal Bloodstream Infections by T2 Magnetic Resonance Technology in the Pediatric PopulationBarbara Lucignano, Valeria Cento, Marilena Agosta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Haematologica|July 18, 2020
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed studyHanny Al-Samkari, Raj S Kasthuri, Joseph G Parambil, et al.
Blood Cancer Journal|February 2, 2022
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithmsMaher Albitar, Hong Zhang, Andre Goy, et al.
Blood Advances|July 30, 2020
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLZijun Y Xu-Monette, Hongwei Zhang, Feng Zhu, et al.
Oncoimmunology|August 5, 2021
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphomaHua You, Zijun Y Xu-Monette, Li Wei, et al.
Current Cancer Drug Targets|January 21, 2011
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsB C Potts, M X Albitar, K C Anderson, et al.
Pageof 42